Last reviewed · How we verify
EPCs
At a glance
| Generic name | EPCs |
|---|---|
| Also known as | iPSC EPCs |
| Sponsor | Allife Medical Science and Technology Co., Ltd. |
| Modality | Small molecule |
| Phase | Phase 1 |
Approved indications
Common side effects
Key clinical trials
- EuroPainClinicsStudy IX ( EPCS IX ) (NA)
- Intra-oral Evaluation of Force Decay of Pigmented and Transparent Elastomeric Power Chains: (NA)
- Exercise Endothelial Progenitor Cells (EPCs) and Type 2 Diabetes (NA)
- Role of the Endothelium in Stroke-like Episode Among CDG Patients (NA)
- Impact of Semaglutide on CD34+ EPC and Fat Derived MSC (PHASE4)
- The Enhanced Angiogenic Cell Therapy - Acute Myocardial Infarction Trial (PHASE2)
- Safety and Preliminary Efficacy of Allogeneic Endothelial Progenitor Cells (EPCs) in Patients With Acute Ischemic Stroke (PHASE1)
- Epidural Cortical Stimulation for Depression (NA)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- EPCs CI brief — competitive landscape report
- EPCs updates RSS · CI watch RSS
- Allife Medical Science and Technology Co., Ltd. portfolio CI